According to a lecture of a MHLW representative, the total number of cases including regenerative medicine submitted to MHLW by the end of January 2017 exceeded 3,500. Of these, 109 were submissions for clinical studies, 17 among them concerning human ES or iPS cells (high risk category 1).

Presentation of Mr Tigashima, MHLW, at 16th Annual Meeting of the Japanese Society for Regenerative Medicine